Title: Global Hemophilia Market Report: 2016 Edition - New Report by Koncept Analytics
1Global Hemophilia Market Report
----------------------------------------- 2016
View Report Details
2View Report Details
- Executive Summary
- Hemophilia refers to a set of hereditary genetic
disorders that impairs the body's ability to
control blood clotting, which controls bleeding
when a blood vessel is broken. People with
hemophilia lack, either partially or completely,
an essential clotting factor needed to form
stable blood clots. In the absence of a
treatment, uncontrolled internal bleeding can
occur, causing stiffness, pain, severe joint
damage and even death. Depending upon the
coagulation factor deficiency, there are
different types of hemophilia such as Hemophilia
A, Hemophilia B, Hemophilia C, Von Willebrand
disease and Hemophilia with Inhibitors. - Even though Hemophilia is rare bleeding disorder,
the number of people affected by it has been
increasing with time. While mild hemophilia is
easy to diagnose especially in kids, when they
learn to move and walk, and get large bruises
from minute falls, severe hemophilia patients
need to go for periodic transfusion of the
respective factors so as to avoid the event of
life-threatening bleeding episodes. Such a
periodic transfusion is done through what is
commonly known as the replacement therapy. With
increasing sophistication and modernization of
technology, demand for advanced treatment options
increases, thereby making the entire market grow. - The key factors which are anticipated to drive
this market include increasing penetration of
recombinant factor VIII, increasing healthcare
expenditure, emerging use of treatments in low
income countries and increasing diagnosis rates.
Some of the noteworthy progresses of this
industry include the increasing adoption of
prophylaxis therapy, introduction of extended
half-life products and gene therapy. However, the
growth of respective industry is challenged by
the high cost of treatments and high reluctance
by patients to switch to new treatments/products. - The report provides a comprehensive study of
global hemophilia market and also major regional
markets. Furthermore, market dynamics such as key
trends and development and challenges are
analyzed in depth. The global hemophilia industry
is highly competitive consisting of several large
companies including the Shire Plc, Bayer Group,
Pfizer Inc, Novo Nordisk etc. The competitive
landscape of the respective market, along with
the company profiles of the leading players are
also discussed in detail.
3Even though Hemophilia is a rare bleeding
disorder, the number of people affected by it has
been increasing with time.
Global Hemophilia Prevalence (2015)
- In the year 2015, it is recorded that the total
number of people affected by hemophilia across
the globe, accounts to xx thousand persons - The global hemophilia market revenue, excluding
the revenue for Von Willebrand disease, for the
year 2015 is estimated to be USxx.x billion. - It is forecasted that the demand for prophylaxis
FVIII will rise at a CAGR of x.xx over the
period 2015-2017, while the demand for
recombinant FVIII will rise at a CAGR of xx.x
over the same period, amounting to xx billion
units and xx billion units respectively, by the
end of 2017.
Global Hemophilia Market Revenue (2015E-2020F)
Global FVIII Demand by Category - Volume
(2015E-2017E)
4Due to increased use of prophylaxis in the US, as
well as pharmaceutical companies expansion of
markets, the US hemophilia market revenue has
witnessed a steady growth over time
The US Hemophilia Patients Treated per Year
(2013-2020F)
- The number of persons treated in the year 2015 is
estimated to be xxx thousand, rising from xxx
thousand in the previous year. Further, it is
forecasted that this number of hemophilia
patients treated will rise at a CAGR of x.xx
over the period spanning 2016-2020. - The US hemophilia A market revenue is estimated
to have risen from USxxx billion in 2014 to
USxxx3 billion in 2015, with a YoY change of
xx. It is forecasted that the revenue will rise
further in future at a CAGR of xx during the
five year period spanning 2016-2020, recording
USxxx1 billion in 2020F. - It is estimated that the revenue for 2015 has
increased to USxxx.xx million, from US551 xxx.x
to grow at a CAGR of xx during the period
spanning 2016-2020, amounting to nearly USxxx
million in 2020.
The US Hemophilia B Market Revenue (2013-2020F)
The US Hemophilia A Market Revenue (2013-2020F)
5Recombinant FVIII has significantly higher use in
developed countries, whereas emerging markets
witness an increasing acceptance as they develop.
The US Von Willebrand Factor Market Revenue
(2013-2020F)
- The US Von Willebrand factor revenue is estimated
to have grown from USxxx million in 2014 to
USxxx million in 2015 and is forecasted to grow
further at a CAGR of xx.2 over the period
2016-2020, amounting to USxxx million in the
year 2020F. - The number of hemophilia A patients in Europe is
estimated to have risen from xx thousand persons
in 2014 to xx persons in 2015, with a YoY rise of
xx.x5. - It is estimated that there were nearly xxx
thousand patients of hemophilia B in Europe in
2015 and it is forecasted that with the number of
patients in this segment will reach nearly xxx.x
thousand by the year 2020.
Europe Hemophilia B Patients (2015E-2020F)
Europe Hemophilia A Patients (2014-2020F)
6Contact Us
View Report Details
These are abridged and sanitized sample pages
from the comprehensive report on the Global
Hemophilia Market . To know more about this
report or for any customized research
requirement, please contact the following
Koncept Analytics CS-36, Second Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T.
91-120-4130959 C 91-9811715635
vikas_at_konceptanalytics.com
Vikas Gupta BD Manager
www.konceptanalytics.com